The Cambridge biotech is working on new ways to discover and develop “agonist antibodies,” and its Series A round was co-led by Atlas Venture and BVF Partners.
Source link
Atlas-backed Diagonal Therapeutics launches with $128M
La Potencia Mas Caliente